上海市青浦区2015—2018年含脊髓灰质炎成分疫苗预防接种安全性监测

仲文江; 费金花; 王贞懿; 项俭; 倪春芳; 潘俊锋

doi:10.19428/j.cnki.sjpm.2019.19325

上海市青浦区2015—2018年含脊髓灰质炎成分疫苗预防接种安全性监测

Safety monitoring on vaccination with poliomyelitis component in Qingpu District of Shanghai, 2015-2018

摘要

摘要:
目的评价上海市青浦区含脊髓灰质炎成分疫苗预防接种的安全性。
方法通过中国免疫规划信息管理系统收集上海市青浦区2015—2018年报告的口服脊髓灰质炎减毒活疫苗(OPV)、灭活脊髓灰质炎疫苗(IPV)和无细胞百白破-灭活脊髓灰质炎-b型流感嗜血杆菌联合疫苗(DTaP-IPV-Hib)的疑似预防接种异常反应(AEFI)的监测数据，进行流行病学分析。
结果青浦区2015—2018年间OPV、IPV、DTaP-IPV-Hib疫苗的AEFI报告发生率分别为12.60/10万剂、186.00/10万剂、738.69/10万剂，其中98.26%为一般反应，1.30%为异常反应(过敏性皮疹)；男童均多于女童，发生年龄均以 < 1岁为主，69.57% AEFI发生在接种后≤1 d。第1剂次AEFI报告数高于后续剂次。
结论青浦区含脊髓灰质炎成分疫苗接种安全性良好，但仍需加强监测。

Abstract:
ObjectiveTo evaluate the safety of poliomyelitis-contained vaccines used in Qingpu District of Shanghai.
MethodsWe collected the reported adverse events following immunization(AEFI) cases related to vaccinations of OPV(oral polio vaccine), IPV(inactive polio vaccine), DTaP-IPV-Hib in Qingpu District from 2015 to 2018 via AEFI information management system; then the data were analyzed by epidemiology method.
ResultsDuring the 4-year period, the incidence rates of AEFI related to vaccinations of OPV, IPV, DTaP-IPV-Hib were 12.60 per 100 000, 186.00 per 100 000, 738.69 per 100 000 doses.Of all the AEFI reported, 98.26% were common reactions and 1.30% rare ones (anaphylactic rash).Most of the reported AEFI cases were small children less than one year old, male cases of AEFI being more than female ones.And 69.57% of the reported cases occurred within one day following vaccination.The reported number of AEFI of first dose/time was more than that of follow-up dose/time.
ConclusionThe vaccination of poliomyelitis-contained vaccines is safe enough but the surveillance on AEFI of the vaccination remains to be strengthened so far.

HTML全文

参考文献(10)

施引文献

资源附件(0)